ArticleThe Journal of infectious diseases2015
Development of Prototype Filovirus Recombinant Antigen Immunoassays.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of Lateral-Flow Assay for Rapid Detection of Influenza Virus.BioMed research international · 2020Pooled it
- Article
- Current Challenges for the Effective Management of the COVID-19 Pandemic.Advances in experimental medicine and biology · 2021Article
- Biosensor Technologies in Medicine: from Detection of Biochemical Markers to Research into Molecular Targets (Review).Sovremennye tekhnologii v meditsine · 2021Review
- In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay.Scientific reports · 2020Article
- Label-Free Biosensors for Laboratory-Based Diagnostics of Infections: Current Achievements and New Trends.Biosensors · 2020Review
- Article
- Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19.AIMS microbiology · 2020Review
- Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies.Scientific reports · 2019Article
- A Smartphone-Based Rapid Telemonitoring System for Ebola and Marburg Disease Surveillance.ACS sensors · 2019Article
- Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings.BMJ global health · 2019Article
- Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.PLoS neglected tropical diseases · 2017Article
- Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.The Journal of infectious diseases · 2016Article
- Lateral flow assays.Essays in biochemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
backgroundThroughout the 2014-2015 Ebola outbreak in West Africa, major gaps were exposed in the availability of validated rapid diagnostic platforms, protective vaccines, and effective therapeutic agents. These gaps potentiated the development of prototype rapid lateral flow immunodiagnostic (LFI) assays that are true point-of-contact platforms, for the detection of active Ebola infections in small blood samples.
methodsRecombinant Ebola and Marburg virus matrix VP40 and glycoprotein (GP) antigens were used to derive a panel of monoclonal and polyclonal antibodies. Antibodies were tested using a multivariate approach to identify antibody-antigen combinations suitable for enzyme-linked immunosorbent assay (ELISA) and LFI assay development.
resultsPolyclonal antibodies generated in goats were superior reagents for capture and detection of recombinant VP40 in test sample matrices. These antibodies were optimized for use in antigen-capture ELISA and LFI assay platforms. Prototype immunoglobulin M (IgM)/immunoglobulin G (IgG) ELISAs were similarly developed that specifically detect Ebola virus-specific antibodies in the serum of experimentally infected nonhuman primates and in blood samples obtained from patients with Ebola from Sierra Leone.
conclusionsThe prototype recombinant Ebola LFI assays developed in these studies have sensitivities that are useful for clinical diagnosis of acute ebolavirus infections. The antigen-capture and IgM/IgG ELISAs provide additional confirmatory assay platforms for detecting VP40 and other ebolavirus-specific immunoglobulins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.